Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
It's like watering and fertilizing plants - it supports their growth and protects them from pests
Reinventing a familiar molecule Veradermics, meanwhile, is taking a more formulation-driven approach
The transformative breakthroughs in GLP-1 research recognized by the 2024 Lasker~DeBakey award
[1] Orforglipron is also chemically different from previous oral GLP-1s
Chatzistefanou I, Kolokythas A, Vahtsevanos K, Antoniades K
